UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1

Drugs in Context, 2024-07, Vol.13, p.1-8

Morabito, Alessandro

2024

Volltextzugriff (PDF)

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?

BMC medicine, 2018-02, Vol.16 (1), p.24-24, Article 24

Morabito, Alessandro

2018

Volltextzugriff (PDF)

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-11, Vol.379 (21), p.2027-2039

2018

Volltextzugriff (PDF)

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

Journal of clinical oncology, 2015-03, Vol.33 (8), p.910-915

2015

Volltextzugriff (PDF)

Angiogenesis Inhibitors in NSCLC

International journal of molecular sciences, 2017-09, Vol.18 (10), p.2021

2017

Volltextzugriff (PDF)

Underground Pumped Storage Hydropower Case Studies in Belgium: Perspectives and Challenges

Energies (Basel), 2020-08, Vol.13 (15), p.4000

2020

Volltextzugriff (PDF)

Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation

PloS one, 2019-07, Vol.14 (7), p.e0219597-e0219597

2019

Volltextzugriff (PDF)

Angiogenesis Inhibitors in Small Cell Lung Cancer

Frontiers in oncology, 2021-05, Vol.11, p.655316-655316

2021

Volltextzugriff (PDF)

Pump as turbine applied to micro energy storage and smart water grids: A case study

Applied energy, 2019-05, Vol.241, p.567-579

2019

Volltextzugriff (PDF)

Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions

The oncologist (Dayton, Ohio), 2006-07, Vol.11 (7), p.753-764

2006

Volltextzugriff (PDF)

Immunotherapy in Small Cell Lung Cancer

Cancers, 2020-09, Vol.12 (9), p.2522

2020

Volltextzugriff (PDF)

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non‐Small Cell Lung Cancer: Results from a Real‐World Population

The oncologist (Dayton, Ohio), 2019-11, Vol.24 (11), p.e1165-e1171

2019

Volltextzugriff (PDF)

The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells

International journal of molecular sciences, 2024-05, Vol.25 (9), p.4844

2024

Volltextzugriff (PDF)

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

The lancet oncology, 2003-10, Vol.4 (10), p.605-615

2003

Volltextzugriff (PDF)

Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions

The oncologist (Dayton, Ohio), 2009-04, Vol.14 (4), p.378-390

2009

Volltextzugriff (PDF)

Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-04, Vol.27 (11), p.1836-1843

2009

Volltextzugriff (PDF)

CFD-based analysis of pumped storage power plants implementing hydraulic short circuit operations

Applied energy, 2024-09, Vol.369, p.123474, Article 123474

2024

Volltextzugriff (PDF)

Cross-reactive CD8 + T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs)

Journal of experimental & clinical cancer research, 2024-03, Vol.43 (1), p.87-87, Article 87

2024

Volltextzugriff (PDF)

Editorial: Small cell lung cancer: New drugs and strategies

Frontiers in medicine, 2023-01, Vol.10, p.1140642-1140642

2023

Volltextzugriff (PDF)

Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC

International journal of molecular sciences, 2020-07, Vol.21 (14), p.4927

2020

Volltextzugriff (PDF)

Lurbinectedin in small cell lung cancer

Frontiers in oncology, 2022-08, Vol.12, p.932105

2022

Volltextzugriff (PDF)

Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis

Journal of translational medicine, 2021-03, Vol.19 (1), p.132-132, Article 132

2021

Volltextzugriff (PDF)

1 – 25 von 509

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(462)
Mit Volltextzugriff
(421)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(375)
Life Sciences & Biomedicine
(335)
Humans
(255)
Oncology
(161)
Female
(146)
Male
(122)
Aged
(112)
Middle Aged
(110)
Adult
(86)
Tumors
(64)
Chemotherapy
(61)
Lung Neoplasms - Drug Therapy
(61)
Lung Cancer
(59)
Biological And Medical Sciences
(58)
Aged, 80 And Over
(56)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(52)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(52)
Medical Sciences
(51)
Treatment Outcome
(48)
Mutation
(46)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Angiogenesis Inhibitors in NSCLC

Underground Pumped Storage Hydropower Case Studies in Belgium: Perspectives and Challenges

Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation

Angiogenesis Inhibitors in Small Cell Lung Cancer

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Pump as turbine applied to micro energy storage and smart water grids: A case study

Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions

Immunotherapy in Small Cell Lung Cancer

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non‐Small Cell Lung Cancer: Results from a Real‐World Population

The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial

Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions

Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

CFD-based analysis of pumped storage power plants implementing hydraulic short circuit operations

Cross-reactive CD8 + T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs)

Editorial: Small cell lung cancer: New drugs and strategies

Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC

Lurbinectedin in small cell lung cancer

Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis

Suchergebnisse filtern